LONG MINI FUTURE WARRANT - NOVO-NORDISK B | Market Closed - BOERSE MUENCHEN 19:26:19 31/05/2024 BST | ||
| 177.7 EUR | +1.36% |
|
| 1 month | +3.44% | ||
| 3 months | +18.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 177.7 | +1.36% |
| 30/05/24 | 175.3 | +0.85% |
| 29/05/24 | 173.8 | -0.25% |
| 28/05/24 | 174.3 | -1.01% |
| 27/05/24 | 176.1 | -1.26% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 07:26 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GH7D46 |
| ISIN | DE000GH7D468 |
| Date issued | 11/06/2021 |
| Strike | 264.9 kr |
| Maturity | Unlimited |
| Parity | 0.5 : 1 |
| Emission price | 3.85 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 181.4 € |
|---|---|
| Lowest since issue | 15.03 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
